

GRADUATORIE BANDO AIFA RICERCA INDIPENDENTE 2023

“SEQUENZIAMENTO TERAPEUTICO IN ONCOLOGIA”

CARCINOMA POLMONARE NON A PICCOLE CELLULE						
N	Istituzione proponente	Titolo	Codice	Punteggio	Budget in euro	Esito
1	Dipartimento di Oncologia, Università di Torino	<i>IDentify the best therapeutic sequenCing strAtegy in oncogene addIcted NSCLC: the DYNAmIC study</i>	AIFA-ONCO-114	41,00	2.499.608,85	Vincitore, ammesso al finanziamento
2	Istituto Nazionale Tumori IRCCS, Fondazione G. Pascale, Napoli	<i>The NSCLC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced non-small-cell lung cancer. The Journey of Lung Cancer Patient - J-Lu</i>	AIFA-ONCO-97	40,00	2.495.243,80	Idoneo non ammesso al finanziamento
3	Azienda Universitaria Ospedaliera Policlinico Umberto I, Roma	<i>Gut microbiota modulation in patients affected by stage IV non small mall cell lung cancer (NSCLC) candidates for first line treatment with chemo-immunotherapy (C-IT) or immunotherapy (IT)</i>	AIFA-ONCO-72	33,00	2.500.000,00	Idoneo non ammesso al finanziamento

4	Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia	<i>Multicenter, randomized, open-label, phase III study of single-agent immunotherapy with or without chemotherapy followed by maintenance immunotherapy for first-line treatment of metastatic non-small cell lung cancer (mNSCLC) with PD-L1 =50% and baseline high tumor burden (trial INTENSIT)</i>	AIFA-ONCO-61	33,00	443.937,00	Idoneo non ammesso al finanziamento
5	IRCCS Ospedale San Raffaele, Milano	<i>Osimertinib and chemotherapy combination sequences by liquid biopsy in patients with EGFR-mutated advanced non-small cell lung cancer (Rise-Down)</i>	AIFA-ONCO-55	30,50	2.313.040,00	Idoneo non ammesso al finanziamento

CARCINOMA RENALE

N	Istituzione proponente	Titolo	Codice	Punteggio	Budget in euro	Esito
1	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	<i>Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A</i>	AIFA-ONCO-112	41,50	2.476.122,00	Vincitore, ammesso al finanziamento

		<i>randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial</i>				
2	Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma	<i>Randomised phase II study comparing the sequential therapy with the combination of anti-VEGFR tyrosine kinase inhibitors plus anti-PD1 monoclonal antibody followed by maintenance with anti-PD1 alone over standard treatment with the continuous therapy with anti-VEGFR tyrosine kinase inhibitors plus anti-PD1 monoclonal antibody or the combination of anti-PD1 plus anti-CTLA4 for treatment of metastatic renal cell carcinoma</i>	AIFA-ONCO-135	39,50	2.496.80,00	Idoneo non ammesso al finanziamento
3	IRCCS Ospedale San Raffaele, Milano	<i>A randomized, phase 3, noninferiority trial investigating a treatment interruption strategy, compared to continuous therapy, and the effects of therapeutic rechallenge in patients with advanced clear cell renal cell carcinoma (ccRCC) benefiting with a major response from frontline immune-TKI combination therapy</i>	AIFA-ONCO-91	26,50	1.802.050,88	Idoneo non ammesso al finanziamento

EPATOCARCINOMA

N	Istituzione proponente	Titolo	Codice	Punteggio	Budget in euro	Esito
1	ASL Napoli 1 Centro, Napoli	<i>The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced epatocellular carcinoma. The Journey of liver cancer patient - J-LI</i>	AIFA-ONCO-16	44,00	2.468.818,20	Vincitore, ammesso al finanziamento
2	Università di Pisa	<i>Randomized phase 3 trial of atezolizumab plus continuous bevacizumab followed by sorafenib compared with atezolizumab plus intermittent bevacizumab followed by sorafenib in advanced hepatocellular carcinoma: the ILLUMINATE trial</i>	AIFA-ONCO-87	37,00	968.600,00	Idoneo non ammesso al finanziamento
3	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	<i>Neoadjuvant immunotherapy in intermediate-advanced HCC eligible to liver transplantation: a parallel cohorts prospective trial</i>	AIFA-ONCO-120	35,50	785.889,04	Idoneo non ammesso al finanziamento